LabConnect and The Bracken Group Form Strategic Collaboration to Enhance Radiopharmaceutical Trial Support

LabConnect, a leading provider of global central laboratory and support services for clinical trials, has announced a strategic collaboration with The Bracken Group to enhance its radiopharmaceutical support capabilities. This partnership comes at a critical time as industry growth for radiopharmaceutical expertise continues to surge, with estimates ranging between 15% and 20% annually. The collaboration positions LabConnect to better serve biotech and pharmaceutical clients advancing targeted treatments and diagnostics in this rapidly expanding field.

The Bracken Group brings significant scientific leadership and strategic expertise to the partnership, having established itself as a key opinion leader with a broad scientific approach across development, regulatory, and commercialization efforts. Wes Wheeler, CEO at LabConnect, emphasized the strategic importance of this collaboration, stating that the partnership creates a unique opportunity to integrate operational excellence with deep scientific acumen. The combination of LabConnect's operational capabilities with Bracken's expertise strengthens the ability to support global clients facing complex logistical and analytical challenges specific to radiopharmaceutical trials.

Colin Miller, PhD, CEO at Bracken Consulting, noted that LabConnect's commitment to innovation aligns with Bracken's mission, creating what he described as an unmatched bridge between medicine, science, and operations in the industry. Miller further explained that Bracken's position as the global leader in consulting for radiopharmaceutical development from pre-clinical to market strategy, combined with LabConnect's capabilities, establishes the partnership as the go-to organization for clients developing both diagnostics and radiolabeled therapy products. The collaboration will focus specifically on enhanced service delivery in critical areas such as sample processing, logistics, and scientific oversight.

This partnership addresses the specialized requirements of the highly regulated radiopharmaceutical field, where precise handling and analytical capabilities are essential for successful clinical trials. The integration of Bracken's consulting expertise with LabConnect's laboratory services creates a comprehensive solution for companies working in targeted radiation therapies and diagnostic imaging agents. As the radiopharmaceutical market continues its rapid expansion, this collaboration represents a significant advancement in supporting the development of next-generation nuclear medicine products that require specialized handling, analysis, and regulatory navigation. More information about LabConnect's services can be found at https://www.labconnect.com, while details about The Bracken Group's expertise are available at https://www.thebrackengroup.com.